Introducing Lumixyl Revitaleyes Brightening Eye Cream


What makes Lumixyl Revitaleyes special? 

It is the first and only eye cream formulated with decapeptide-12 as part of a truly comprehensive treatment to correct dark circles, eye-area lines and wrinkles, dryness and inflammation. Most other products tackle just one or two of these issues, leaving behind unresolved problems. First introduced in the popular Lumixyl Brightening Creme, decapeptide-12 is theStanford University developed technology that is clinically shown to reduce the appearance of hyperpigmentation in skin without causing the irritation or redness associated with other brands. Combined with other potent ingredients, Lumixyl Revitaleyes addresses all of the major contributing factors to dark circles under the eyes. The result is brightness, smoothness, and firmness that is truly age defying.
"Our formula pairs industry proven ingredients that help with dermal iron deposits and inflammation with our proprietary skin brightening decapeptide-12 technology, making Revitaleyes the most comprehensive, professional-strength treatment for dark under-eye circles on the market today," states Felipe Jimenez, Ph.D., Chief Scientific Officer for Envy Medical.
In fact, Lumixyl Revitaleyes Brightening Eye Cream expertly addresses the six biggest eye-area complaints, including:
HYPERPIGMENTATION
IRON DEPOSITS
INFLAMMATION
DRY LINES
WRINKLES
These proven potent ingredients are together for the first time, delivering improved eye lift, tone, texture and vitality never before achieved by a standard eye cream.
SOURCE Envy Medical Inc.
Lumixyl Revitaleyes
Lumixyl Revitaleyes

Lumixyl Revitaleyes is the newest edition to the Lumixyl range of products and is the first eye cream formulated with decapeptide-12. This remarkable eye cream has been developed to comprehensively treat and correct dark circles, eye-area fine lines and wrinkles, dryness and inflammation. The result is brighter, smoother and firmer skin under the eyes, giving you a younger, more youthful appearance.

No comments:

Post a Comment